Tirzepatide to prevent atrial fibrillation return after ablation in obesity
Treatments studied
Part of Heart & circulation, Hormones & metabolism clinical trials.
This trial tests whether tirzepatide, a medication for weight and blood sugar, can reduce the chances of atrial fibrillation (an irregular heartbeat) coming back after a heart procedure called catheter ablation in people with overweight or obesity. It may help by addressing weight-related factors that contribute to heart rhythm problems.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have symptomatic atrial fibrillation (paroxysmal or persistent) confirmed by a doctor, with persistent cases lasting 7 days or more and total history under 5 years.
- You have a body mass index (BMI) of 28 or higher, or a BMI of 24 to 28 with at least one weight-related condition like high blood pressure, diabetes, or sleep apnea.
- You are scheduled to have a catheter ablation for atrial fibrillation and that procedure successfully restores normal rhythm.
- You cannot take or have not responded to at least one heart rhythm medication, or you prefer a rhythm-control approach.
- You can do basic physical activity like moderate walking and are willing to attend follow-ups for 12 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether the drug tirzepatide (used for weight loss) can help reduce the return of atrial fibrillation after a catheter ablation procedure. It is for people with persistent AFib who are overweight and have another weight-related health condition.
This trial tests whether tirzepatide, a weight-loss and blood-sugar medication, can help prevent atrial fibrillation (AFib) from coming back after a catheter ablation procedure. The study focuses on people with obesity or overweight and heart problems, particularly those with a stiff heart (HFpEF).
This study tests whether tirzepatide, a medication that helps with weight loss and blood sugar control, can improve the heart rhythm condition atrial fibrillation. If you have AFib and are overweight or obese, this trial may be an option for you.
This study tests if tirzepatide can improve heart and metabolic health in overweight or obese adults with congenital heart disease. It may offer a new treatment option for weight loss when lifestyle changes alone haven't worked.
This trial tests a medicine called tirzepatide, given as an injection, to see if it can improve daily function and symptoms in people with a weak heart (heart failure with reduced ejection fraction) who also have obesity. Tirzepatide works on two natural hormones to help with weight and may also improve heart health.
This trial tests whether a weight loss medication (semaglutide) given before and after a first-time heart ablation procedure for atrial fibrillation can improve outcomes. It is for people who are overweight or obese and have certain related health conditions.
Hear when a new Atrial fibrillation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.